Document Detail


Absence of change of signal-averaged electrocardiogram identifies patients with ventricular arrhythmias who are non-responders to amiodarone.
MedLine Citation:
PMID:  11959384     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The aim of this study was to assess the ability of a non-invasive study, the signal-averaged ECG (SAECG), to predict the effect of amiodarone at ventricular level. BACKGROUND: Amiodarone is the main drug drug used in the treatment of ventricular arrhythmias. Standard ECG does not detect any change in QRS complex resulting from amiodarone therapy. SAECG is more sensitive than ECG for detecting changes in QRS complex. METHODS: The study examined the effects of amiodarone on SAECG in relation to the results of programmed ventricular stimulation in 68 patients with old myocardial infarction, spontaneous and inducible sustained ventricular tachycardia (VT). RESULTS: Amiodarone prolonged the total QRS duration (dur) (129+/-28 vs. 140+/-30 ms, P<0.05) and low amplitude signal (LAS) dur (45+/-20 vs. 51+/-20 ms, P<0.1), whereas the root-mean-square voltage of the last 40 ms of QRS complex (RMS 40) was significantly reduced (20+/-16 vs. 14+/-9 microV, P<0.05). Changes in SAECG parameters did not differ significantly in patients in whom amiodarone prevented the inducibility of VT (n=15) and those in whom VT remained inducible with amiodarone (n=53), but in baseline QRS duration was significantly shorter in patients in whom amiodarone prevented the VT induction (118+/-26 vs. 133+/-28 ms, P<0.05). In patients in whom amiodarone did not prolong the cycle length of VT (n=15), SAECG did not change significantly (QRS dur 131+/-29 vs. 132+/-27 ms, LAS 42+/-20 vs. 42+/-19 ms, RMS 40 22+/-14 vs. 19+/-11 microV). Comparison of the SAECG data in patients with no inducible VT and those with slowed VT differed significantly (P<0.05) between the control state and the recording with amiodarone. CONCLUSIONS: The effects of amiodarone on VT inducibility are predicted by a shorter baseline QRS duration and the degree of drug-induced prolongation of filtered QRS duration. Amiodarone prolonged the QRS duration, LAS duration and decreased RMS 40; this effect was more important in patients with no inducible VT and in those with only slowed VT, than in patients with unchanged or accelerated VT. The absence of changes of QRS duration predicted the induction of a more rapid or not slowed VT with amiodarone with a sensitivity of 87% and a specificity of 83%. Therefore, SAECG appears as an useful and simple means to predict the effects of amiodarone in patients with myocardial infarction and VT.
Authors:
Béatrice Brembilla-Perrot; Olivier Claudon; Pierre Houriez; Daniel Beurrier; Christine Suty-Selton
Related Documents :
19474054 - Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmi...
15667654 - Life-threatening ventricular arrhythmia recognition by nonlinear descriptor.
20384654 - Electroanatomical mapping-guided endocardial and epicardial ablation of sustained ventr...
1715124 - Effects of enflurane on inducibility of ventricular tachycardia.
20671864 - Acute ischemic stroke in a patient with a native valvular strand.
1566904 - Oxygen uptake during early cardiogenesis of the chick.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  International journal of cardiology     Volume:  83     ISSN:  0167-5273     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2002 Apr 
Date Detail:
Created Date:  2002-04-17     Completed Date:  2002-06-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  47-55     Citation Subset:  IM    
Affiliation:
Cardiologie, CHU Brabois, 54500, Vandoeuvre Les Nancy, France. b.brembilla-perrot@chu-nancy.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Amiodarone / therapeutic use*
Anti-Arrhythmia Agents / therapeutic use*
Electrocardiography* / methods
Electrophysiologic Techniques, Cardiac
Female
Follow-Up Studies
Heart Conduction System / drug effects
Humans
Male
Middle Aged
Predictive Value of Tests
Recurrence
Severity of Illness Index
Statistics as Topic
Stroke Volume / physiology
Survival Analysis
Tachycardia, Ventricular / drug therapy*,  mortality,  physiopathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina.
Next Document:  Hemodynamic basis of the reduced oxygen uptake relative to work rate during incremental exercise in ...